Chen, Y., Hong, H., Fang, W., Zhang, X., Luo, H., Chen, Z., . . . Peng, Y. (2023). Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study. Frontiers Media S.A.
Chicago Style (17th ed.) CitationChen, Yongbiao, et al. Toripalimab in Combination with Anlotinib for Unresectable Hepatocellular Carcinoma After SBRT: A Prospective, Single-arm, Single-center Clinical Study. Frontiers Media S.A, 2023.
MLA (9th ed.) CitationChen, Yongbiao, et al. Toripalimab in Combination with Anlotinib for Unresectable Hepatocellular Carcinoma After SBRT: A Prospective, Single-arm, Single-center Clinical Study. Frontiers Media S.A, 2023.
Warning: These citations may not always be 100% accurate.